ArticleBrain and behavior2025
Specific Marker Gene Analysis for Primary Central Nervous System Lymphoma Based on Methylation Difference and Development of Detection Primers.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrimary central nervous system lymphoma (PCNSL) is a central nervous system disease with high mortality, wide variation in symptoms, and difficult diagnosis. The development of molecular markers for PCNSL is still in its initial stages.
methodsThe databases were analyzed by 450 K and RRBS, and the differential gene structure was displayed through Venn diagram, heatmap, and enrichment. ROC and survival curve analyses were performed on the marker genes. The specificity of PCNSL in blood samples of patients was verified by qPCR, and the sensitivity of the detection primers was verified by in vitro methylation and demethylation drug treatment cell experiments.
resultsTwenty-six sites were identified using 450 K microarray analysis. The RRBS analysis team found 14,867 sites. The methylation site located in the promoter region of REHB was verified, and the results showed that the primers for this site were able to distinguish patients with PCNSL and were sensitive to the detection of methylation levels.
conclusionsA pair of methylation primers targeting the RHEB promoter region were obtained, which demonstrated the potential to distinguish patients with PCNSL from those with other CNS diseases. These findings should be considered preliminary and serve as proof-of-concept for further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.